Table 4. Cost results breakdown–per patient per month (ABA-1L vs. TNFi-1L).

	ABA-1L	TNFi-1L	Incremental costs (ABA-1L –TNFi-1L)
Total costs per PMPM
bDMARD	73,057	74,513	-1,456
Concomitant medication	2,151	2,163	-12
Monitoring	19,376	19,376	0
AEs occurring ≥5%	0	0	0
SAEs	3,173	3,430	-257
Hospitalisations due to infections	612	459	153
Total	98,369	99,940	-1,571

1L, first line; ABA, abatacept; AE, adverse event; bDMARD, biological disease-modifying antirheumatic drug; PMPM, per member per month; SAE, serious AE; TNFi, tumour necrosis factor inhibitor.